89889-52-1

Basic information

• Product Name: BIOTIN-XX-NHS
• Synonyms: N-SUCCINIMIDYL N-6-(BIOTINYLAMINO)CAP- &;6-(BIOTINAMIDOCAPROYLAMIDO)CAPROIC ACID N-HYDROXYSU;n-Succinimidyln-6-(biotinylamino)caproyl-6-aminocaproatabout90%;6-[6-(Biotinylamino)hexanoylamino]hexanoicacidN-hydroxysuccinimideester;5-[5-(N-SUCCINIMIDYLOXYCARBONYL)PENTYLAMIDO]HEXYL D-BIOTINAMIDE (BIOTIN-(AC5)2-OSU);6-((+)-Biotinamidohexanoylamino)hexanoic acid N-hydroxysuccinimide ester;Biotin-X-X-NHS, N-Succinimidyl N-[6-(biotinylamino)caproyl]-6-aminocaproate, 6-(Biotinamidocaproylamido)caproic acid N-hydroxysuccinimide ester;LC-LC-NHS-(+)-Biotin
• CAS NO: 89889-52-1
• Molecular Formula: C₂₀H₃₀N₄O₆S
• Molecular Weight: 567.7
• EINECS: 205-525-8
• Product Categories: Biotin Derivatives;Cross Linking Reagents
• Mol File: 89889-52-1.mol

Chemical Properties

• Melting Point: 147-151°C
• Appearance: /powder
• Density: 1.29±0.1 g/cm3(Predicted)
• Storage Temp.: −20°C
• Solubility: DMF: 25 mg/mL
• PKA: 13.90±0.40(Predicted)
• Stability: Moisture Sensitive
• BRN: 8377428
• CAS DataBase Reference: BIOTIN-XX-NHS(CAS DataBase Reference)
• NIST Chemistry Reference: BIOTIN-XX-NHS(89889-52-1)
• EPA Substance Registry System: BIOTIN-XX-NHS(89889-52-1)

Safety Data

• WGK Germany: 3
• F: 10-21
• Hazardous Substances Data: 89889-52-1(Hazardous Substances Data)

Usage

Uses

Used in Bioconjugation:
BIOTIN-XX-NHS is used as a biotinylation reagent for the attachment of biotin to various molecules, including proteins, peptides, and small molecules, to enable their detection, purification, or immobilization.
Used in Human IgM Biotinylation:
BIOTIN-XX-NHS is used as a biotinylation reagent for the modification of human IgM antibodies, allowing for their detection and analysis in various immunoassays.
Used as a Cross-linking Reagent:
BIOTIN-XX-NHS is used as a biotinylated cross-linking reagent to form stable covalent bonds between molecules, facilitating the study of molecular interactions and the development of novel bioconjugates.

Upstream product

• 35013-72-0 biotin N-Hydroxysuccinimide ester 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 72040-64-3 N-(+)-biotinyl-6-aminocaproic acid 
• 60-32-2 6-aminohexanoic acid 
• 74124-79-1 di(succinimido) carbonate 
• 1306616-52-3 cyanomethyl biotinate 
• 58-85-5 biotin 

Downstream Products

• 440358-98-5 N-{6-[3-(N-cholesteryl-2-nitrobenzenesulfonamido)propylamino]-6-oxohexyl}biotinamide 
• 1309586-30-8 C₁₃₉H₂₁₅N₂₃O₆₃S 
• 1243680-51-4 2-(2-acetoxy-5-(2-chloroethyl)benzyl)-4-(3-(6-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)hexanamido)prop-1-ynyl)phenyl acetate 
• 331722-78-2 4-(N-(S-(N-(6-((6-((biotinoyl)amino)hexanoyl)amino)hexanoyl)glutathionyl)acetyl)-amino)phenylarsenoxide 
• 1141894-56-5 C₆₇H₉₉N₉O₁₁S₂ 
• 1141894-57-6 C₆₇H₉₉N₉O₁₁S₂ 
• 1141486-32-9 C₆₇H₉₉N₉O₁₂S₂ 
• 1141486-33-0 C₆₉H₁₀₁N₉O₁₃S₂ 
• 1141486-17-0 C₆₉H₁₀₁N₉O₁₁S₂ 
• 1141486-40-9 C₆₉H₁₀₁N₉O₁₂S₂ 
• 1141486-41-0 C₆₉H₁₀₃N₉O₁₁S₂ 

Relevant articles and documents

Synthesis and in?vitro anticancer activities of biotinylated derivatives of glaucocalyxin A and oridonin

Fourteen glaucocalyxin A biotinylated derivatives, one glaucocalyxin C biotinylated derivative, and two oridonin biotinylated derivatives were designed and synthesized. Their structures were confirmed from 1H NMR, 13C NMR and HRMS data. The derivatives were evaluated for cytotoxic activities against lung (A549), cervical cancer cell line HeLa derivative (KB), multidrug-resistant KB subline (KB-VIN), triple-negative breast (MDA-MB-231), and estrogen receptor-positive breast (MCF-7) cancer cell lines. (Figure presented.).

Novel N-acetyl-Glycol-split heparin biotin-conjugates endowed with anti-heparanase activity

Heparanase is regarded as a promising target for anticancer drugs and Ronepastat is one of the most promising heparanase inhibitors insert in clinical study for Multiple Myeloma Therapy. To improve its pharmacokinetic/pharmacodynamic profile, as well to have an antidote able to neutralize its activity in case of over dosages or intolerance, a new class of its derivatives was obtained inserting non-carbohydrate moieties of different length between the polysaccharide chain and biotin or its derivatives. In vitro these novel derivatives maintain the anti-heparanase activity without induced toxicity. The newly synthesized compounds retained the ability to attenuate the growth of CAG myeloma tumors in mice with potency similar, or in one case even higher than that of the reference compound Roneparstat as well as inhibited metastatic dissemination (lung colonization) of murine B16-F10 melanoma cells in vivo.

COMPOSITION AND METHODS FOR IMAGING CELLS

A composition for imaging a cell includes a first imaging probe and a second imaging probe that include respectively a first reporter moiety and a second reporter moiety. The first reporter moiety and the second reporter moiety form a signaling complex that produces a detectable signal when the first imaging probe and second imaging probe complex with first and second biomarkers of the cell.

BIOCONJUGATES WITH A CONTROLLED DEGREE OF CONJUGATION, THEIR PROCESS OF PREPARATION, AND THE REAGENTS FOR THEIR PREPARATION

The present invention relates to a process for preparation of heterogeneous monodisperse mixtures of protein conjugates with a defined degree of conjugation (1-8) obtained by using a tri-functional reagent allowing affinity concentration followed by subse

BIOTIN-CONJUGATED N-ACETYL GLYCOL SPLIT HEPARIN

The present invention relates to N-acetyl glycol split heparin molecules conjugated with biotin having following formula (I), wherein the meanings of the substituents are disclosed in the description. The present invention also relates to such compounds for use as medicaments, in particular for the treatment of diseases and disorders associated with heparanase activity, and to pharmaceutical compositions comprising the same.

Corroboration of Zn(ii)-Mg(ii)-tertiary structure interplays essential for the optimal catalysis of a phosphorothiolate thiolesterase ribozyme

The TW17 ribozyme, a catalytic RNA selected from a pool of artificial RNA, is specific for the Zn2+-dependent hydrolysis of a phosphorothiolate thiolester bond. Here, we describe the organic synthesis of both guanosine α-thio-monophosphate and the substrates required for selecting and characterizing the TW17 ribozyme, and for deciphering the catalytic mechanism of the ribozyme. By successively substituting the substrate originally conjugated to the RNA pool with structurally modified substrates, we demonstrated that the TW17 ribozyme specifically catalyzes phosphorothiolate thiolester hydrolysis. Metal titration studies of TW17 ribozyme catalysis in the presence of Zn2+ alone, Zn2+ and Mg2+, and Zn2+ and [Co(NH3)6]3+ supported our findings that Zn2+ is absolutely required for ribozyme catalysis, and indicated that optimal ribozyme catalysis involves the presence of outer-sphere and one inner-sphere Mg2+. A survey of the TW17 ribozyme activity at various pHs revealed that the activity of the ribozyme critically depends on the alkaline conditions. Moreover, a GNRA tetraloop-containing ribozyme constructed with active catalysis in trans provided catalysis and multiple substrate turnover efficiencies significantly higher than ribozymes lacking a GNRA tetraloop. This research supports the essential roles of Zn2+, Mg2+, and a GNRA tetraloop in modulating the TW17 ribozyme structure for optimal ribozyme catalysis, leading also to the formulation of a proposed reaction mechanism for TW17 ribozyme catalysis.

METHOD FOR PREPARING N-SUCCINIMIDYL N-BIOTINYL-6-AMINOCAPROATE

The invention relates to a method for preparing N-succinimidyl N-biotinyl-6-aminocaproate, characterised in that said method includes a step of activating N-biotinyl-6-aminocaproic acid in the form of a mixed anhydride, followed by coupling said mixed anhydride with N-hydroxysuccinimide.